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Abstract
Though overall death from opioid overdose are increasing in the United States, the death rate in some states and population groups is
stabilizing or even decreasing. Several states have enacted a Naloxone Accessibility Laws to increase naloxone availability as an
opioid antidote. The extent to which these laws permit layperson distribution and possession varies. The aim of this study is to
investigate differences in provisions of Naloxone Accessibility Laws by states mainly in the Northeast and West regions, and the
impact of naloxone availability on the rates of drug overdose deaths.
This cross-sectional study was based on the National Vital Statistics System multiple cause-of-death mortality files. The average
changes in drug overdose death rates between 2013 and 2017 in relevant states of the Northeast andWest regions were compared
according to availability of naloxone to laypersons.
Seven states in the Northeast region and 10 states in the Western region allowed layperson distribution of naloxone. Layperson
possession of naloxone was allowed in 3 states each in the Northeast and the Western regions. The average drug overdose death
rates increased in many states in the both regions regardless of legalization of layperson naloxone distribution. The average death
rates of 3 states that legalized layperson possession in the West region decreased (-0.33 per 100,000 person); however, in states in
the West region that did not allow layperson possession and states in the Northeast region regardless of layperson possession
increased between 2013 and 2017.
The provision to legalize layperson possession of naloxone was associated with decreased average opioid overdose death rates in
3 states of the West region.
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1. Introduction
Opioid use disorder and overdose deaths currently pose a
grave threat to public health in the US. According to the
Centers for Disease Control and Prevention (CDC), approxi-
mately 400,000 people died of opioid overdose between
1999 and 2017.[1] Among the strategies implemented to
resolve the issue, an increase in naloxone access by legal
means through Naloxone Access Laws (NALs) has been
proven to be effective in lowering the incidence of opioid
overdose deaths.[2]
Even with strong measures to address the issue, the number of
opioid overdose deaths has been increasing.[1] However, although
the opioid death rates increased in most states, some states were
stabilized or even decreased.[1] According to a CDC report, there
was a 71% increase of overdose death rates between 2013 and
2017 and an increase of 9%per year from1999 to 2011. TheCDC
indicated, by citing previous studies, that opioid-involved death
rate increases were more attributable to illicitly-manufactured
fentanyl than to pharmaceutically-manufactured fentanyl.[3–5]
Fentanyl is 50 to 100 times more potent than morphine and has a
rapid onset of action, leading to immediate respiratory depression
and death. Thus, Reduction of opioid-related mortality rates
requires cooperation among public health and legislative officials,
in addition to improving naloxone accessibility. Public health
authorities should develop more efficient surveillance systems for
detecting and controlling drug overdose outbreaks, and legislative
officials need to enact laws designed to reduce and control these
outbreaks. One of the best options to halt explosive growth of
opioid-involved overdose deaths is to allow laypersons to possess
naloxone without prescription.
States with the highest observed age-adjusted drug overdose
death rates require stronger measures to combat the burgeon-
ing opioid epidemic. In particular, some states in the Northeast,
such as Pennsylvania, New Hampshire, Maine, Massachusetts
and Connecticut, fall into this category.[6] However, previous
studies have found regional imbalances between opioid
overdose treatment capacity and need, especially in the
Northeast states of Pennsylvania, New York and New Jersey.[7]
Naloxone, a competitive opioid antagonist, can rapidly reverse
opioid overdose toxicity.[8] The implementation of NALs
increased accessibility of naloxone to the public in the US
Naloxone administration by bystanders improved the recovery
rate from opioid overdose.[9] However, state naloxone
dispensing rates do not match opioid overdose death rates.[10]
While overdose education and naloxone distribution programs
raised awareness and accessibility, there is possibility of a
mismatch between naloxone possession and use by lay-
persons.[11] The scope and extent of immunity provided by
state legislations also differ; some allow laypersons to possess
naloxone without prescription, but others allow only distribu-
tion.[12] On April 5, 2018, the Office of the Surgeon General
released a statement to urge further expansion of naloxone
availability.[13] The first step in furthering this expansion
should be to amend law to permit layperson naloxone
possession, especially in regions where opioid overdose death
reduction is most needed.
The objective of our study was to evaluate these regional
differences and recent trends in drug overdose death rates in
states with or without NALs.
2. Methods
2.1. Data source
Study design was a serial retrospective cross-sectional data
analysis.[14] We obtained data from the National Vital Statistics
Systems presenting provisional counts for drug overdose deaths
occurring in 50 states and the District of Columbia from 2013 to
2017. The counts represented the number of reported deaths due
to drug overdose occurring in the 12-month periods ending in the
months indicated. Information on state NALs was obtained from
the Prescription Drug Abuse Policy Surveillance Systems as well
as academic and legal sources. Additionally, we referred to the US
Census Bureau Region and Census Division for regional
classifications in reference to states with and without NALs.
Approval by an Institutional Review Board was not necessary
because all data were secondary, de-identified, and publicly
available and patients’ consent was not involved.
2.2. Main measurement and variables of interest
Drugoverdosedeathswere identified in theNationalVital Statistics
Systemmultiple cause-of-death mortality files from data contained
on death certificates.[14] The National Vital Statistics System is an
inter-governmental system to share data regarding the vital
statistics of the US population.[14] The cause of death is coded
based on the International Classification of Disease-10 codes X40-
44 (unintentional), X60-64 (suicide), X85 (homicide), or Y10-14
(undetermined intent). Among deaths with drug overdose as the
underlying cause, the typeof drug ordrug category is demonstrated
by the following International Classification of Disease, 10th
revision, Clinical Modification multiple cause-of-death codes:
T40.0, narcotics andpsychodysleptics; T40.1, heroin; T40.2, other
opioids such as natural and semisynthetic opioids; T40.3,
methadone; T40.4, other synthetic narcotics, excluding metha-
done; T40.5, cocaine; and T43.6, psychostimulants with abuse
potential. Some causes of deaths involvedmore than 1 type of drug,
and thesewere included in rates for eachdrug category; thus, causes
of death in some cases were not mutually exclusive. For example, a
death involving both a synthetic opioid other than methadone and
heroin would be included in both the synthetic opioid other than
methadone and heroin death rates. All annual drug overdose death
rates were presented as number of deaths per 100,000 persons.We
examined theoutcomesof interest, state-level annual drugoverdose
death by region, as defined by the Healthcare Cost and Utilization
Project sponsored by the Agency for Healthcare Research and
Quality. We focused on the Western and Northeastern states,
which are unlikely to have neighboring effects on each other, to
discern which regions need stronger legislative measures.
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2.3. Statistical analysis
We adopted the statistical results from a previous study.[1] The
study performed statistical analysis of state-level average annual
percentage changes in age-adjusted drugoverdose death rates from
2013 to 2017.[1] Annual percentage changes with statistically
significant trends were analyzed using z-tests when the number of
deaths was ≥100 and non-overlapping confidence intervals based
onagammadistributionwhen the numberwas<100. Scholl L et al
described the statistical analysis in more detail.[1]
3. Results
Seven states in the Northeast region and 10 states in the Western
region allowed layperson distribution of naloxone. Layperson
possession of naloxone was allowed in 3 states each in the
Northeast and the Western regions.
Table 1 presents age-adjusted drug overdose death rates
according to state by layperson distribution availability. In the
Northeast region, seven states that allowed layperson distribu-
tion of naloxone showed an increase in age-adjusted drug
overdose death rate between 2013 and 2017. The average
increase in the death rate was 13.57 per 100,000 persons. Two
states in the Northeast region that did not allow layperson
distribution of naloxone showed an average increase in death rate
of 15.12 per 100,000 persons, whichwas slightly higher than that
of the states with naloxone distribution. The Western states
generally showed smaller changes in age-adjusted drug overdose
death rates than those of the Northeast. The 3Western states that
allowed naloxone distribution showed an average increase in
death rate of 0.34 per 100,000 persons; this was significantly
lower than that of the Western states that did not allow naloxone
distribution (6.17 per 100,000 persons).
Table 2 shows age-adjusted drug overdose death rates
according to state by layperson possession. Three Western states
that allowed possession of naloxone showed a -0.33 per 100,000
persons decrease in average overdose death rate. This is the only
group that showed a decrease in drug overdose death rate from
2013 to 2017. The other 10 Western states that did not allow
naloxone possession showed an increase in death rates at an
average of 2.53 per 100,000 persons. In the Northeastern region,
3 states that allowed layperson possession of naloxone showed
significantly smaller increases in death rates, an average of 10.7
per 100,000 persons, compared to the 15.53 per 100,000 persons
average of 6 states that did not allow naloxone possession.
4. Discussion
We found regional variation of drug overdose death rates that
appeared to be associated with scope and extent of NAL
provisions. In the Western region, drug overdose death rates
decreased in the states that allowed layperson naloxone
possession. Sharp increases in drug overdose death rates in the
Northeastern region were partially alleviated in the states
allowing layperson naloxone possession.
Despite efforts to solve the opioid epidemic issue, numbers of
hospitalizations and emergency department visits and net
opioid overdose death rates are on the rise.[4,15,16] However, the
pace at which the overdose death rates has grown differs by
Table 1
Age-adjusted drug overdose death rates according to state by layperson distribution.
Northeast (n=9)
Layperson distribution No layperson distribution
Average change 13.57 Average change 15.15
State 2013 2017 Difference State 2013 2017 Difference
Maine 9.9 29.9 20 Connecticut 12.3 27.7 15.4
New Hampshire 11.8 34 22.2 Massachusetts 13.3 28.2 14.9
New Jersey 7.6 22 14.4
New York 8.3 16.1 7.8
Pennsylvania 7.8 21.2 13.4
Rhode Island 18.1 26.9 8.8
Vermont 11.6 20 8.4
West (n=13)
Layperson distribution No layperson distribution
Average change 0.34 Average change 6.17
State 2013 2017 Difference State 2013 2017 Difference
Alaska 9.2 13.9 4.7 Arizona 8.2 13.5 5.3
California 4.9 5.3 0.4 Idaho 5.7 18.8 13.1
Colorado 8 10 2 Wyoming 8.6 8.7 0.1
Hawaii 4.7 3.4 1.3
Montana 7.2 3.6 3.6
New Mexico 16 16.7 0.7
Nevada 13.7 13.3 -0.4
Oregon 7.5 8.1 0.6
Utah 15.9 15.5 -0.4
Washington 8.9 9.6 0.7
∗
State abbreviations are in alphabetical order.
∗
All death rates are per 100,000 populations.
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states. This difference in pace can partially be explained by the
differences in extent to which lay people have access to
naloxone. States that allowed layperson possession without
prescription demonstrated slower increases in opioid overdose
death rates compared to those that did not.[17] Increasing
possession of naloxone by lay responders is more directly
related to reducing overdose death than increasing distribution.
Although awareness and accessibility of naloxone rose,
naloxone possession may be different from its actual use.[11]
Some speculate that individuals may be reluctant to carry
naloxone in fear of harassment from law enforcement due to the
association between naloxone and opioid use. Therefore,
reducing the stigma attached to possession by legal means will
be pivotal to overdose prevention. Efforts should be made to
make naloxone more available not only by means of treatment
and prescription but also by involving laypersons.
Previous findings suggested that witnessing an overdose or
knowing someone affected by overdose were potential motiva-
tors for first-time naloxone access among lay responders.[18]
However, the general public, including opioid users, may not be
aware of naloxone access. Programs like overdose education and
nasal naloxone distribution programs (OEND) have attempted to
educate opioid users and bystanders to prevent, recognize, and
respond to overdose with use of naloxone. According to the
interrupted time series analysis performed by Walley et al.,
communities where OEND was implemented displayed reduced
opioid overdose death rates compared to those with no
OEND.[19] There needs to be a nationwide effort led by
policy-makers to expand naloxone education programs like
OEND targeting not only opioid users and their families but also
general public.[20]
Naloxone has become more available with implementation of
NALs. However, naloxone’s distribution system needs to be
optimized. Automated external defibrillators (AEDs) have
become widely available and encouraged for public use. Thus,
naloxone kits can be added to the AED cabinets.[21] However,
locating AEDs in public place can be difficult in certain locations,
resulting in greater delay before implementation.[22] If AEDswere
used as landmarks for naloxone kits, the same issue will be
present for administration in an emergent overdose scenario. To
counteract this, a national registry of naloxone kit locations
should be implemented as well. Smartphone technology with a
global positioning system directing bystanders to the location of
the emergency, which has been shown to increase the rates of
cardiopulmonary resuscitation by bystanders, could also be used
to help bystanders locate the nearest naloxone kit.[23] Applica-
tions, such as NaloxoFind, have been used to identify and locate
naloxone within a 2 mile radius and allows communication with
those carrying naloxone.[24] Further promotion of such technol-
ogy will increase use of available naloxone in public.
These results indicate that legislation needs to be revised to
maximize naloxone availability by permitting laypersons to
possess naloxone without prescription, especially in states where
the problems are rising. With statewide adoption of legislation
designed to improve layperson naloxone access, policy-makers
need to assess the effectiveness in delivery and impact of these
policies. The opioid epidemic is a nationwide catastrophe. It can
affect our lives directly or indirectly. To alleviate the opioid crisis,
multidisciplinary approaches by personnel from a variety of fields
such as government, community, and academia are required.
Health professionals, especially opioid prescribers, are also at the
forefront of the fight against the opioid epidemic. These
Table 2
Age-adjusted drug overdose death rates according to state by layperson possession.
Northeast (n=9)
Layperson possession No layperson possession
Average change 10.7 Average change 15.53
State 2013 2017 Difference State 2013 2017 Difference
Massachusetts 13.3 28.2 14.9 Connecticut 12.3 27.7 15.4
Rhode Island 18.1 26.9 8.8 Maine 9.9 29.9 20
Vermont 11.6 20 8.4 New Hampshire 11.8 34 22.2
New Jersey 7.6 22 14.4
New York 8.3 16.1 7.8
Pennsylvania 7.8 21.2 13.4
West (n=13)
Layperson possession No layperson possession
Average change -0.33 Average change 2.53
State 2013 2017 Difference State 2013 2017 Difference
Hawaii 4.7 3.4 1.3 Alaska 9.2 13.9 4.7
New Mexico 16 16.7 0.7 Arizona 8.2 13.5 5.3
Nevada 13.7 13.3 0.4 California 4.9 5.3 0.4
Colorado 8 10 2
Idaho 5.7 18.8 13.1
Montana 7.2 3.6 3.6
Oregon 7.5 8.1 0.6
Utah 15.9 15.5 0.4
Washington 8.9 9.6 0.7
Wyoming 8.6 8.7 0.1
∗
State abbreviations are in alphabetical order.
∗
All death rates are per 100,000 populations.
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professionals should be well-versed in naloxone prescription
practices and education on its proper use. In addition to
legislation of NALs, fund-raising, community education and
training for stakeholders, providing treatment programs and
facilities, and policy-making are necessary. A community
coalition model such as Project Nazarus provides a good
example for us to improve opioid overdose outcomes.[25] Project
Nazarus involves community activation and coalition building,
monitoring and surveillance system, overdose prevention, rescue
medication for reversing drug overdoses, and assessment of
project components. In Project Nazarus, stakeholders from
various sectors such as healthcare, school, police, and substance
abuse facilities, have participated in this model and committed to
engage the support from relevant parts in the community.
Through a community forum, they share information, raise
awareness of the community’s problems, and bring the attention
of other people. In addition, they establish a working coalition
and a community plan and make policies to resolve problems.
Providing naloxone to the public and teaching them its proper use
will improve responsibility and power to reduce the opioid
epidemic. In order to develop sustainable policies, cost-
effectiveness should be considered. Increased naloxone distribu-
tion and possession may increase medical expenditures and the
public health budget. Because opioid use is high contagious and
the consequences can be fatal, health authorities need to pay the
cost even if NALs are not cost-effective. In addition, the ethical
and psychological aspects should be considered. The social effort
to reduce the stigma regarding opioid use and naloxone
possession and emotional supports for drug users to return to
their communities are required. Understanding the biopsy-
chosocial nature of substance disorder and evidence-based
interventions to resolve this growing problem are necessary.
We acknowledge several limitations. First, we did not use
primary death certificate data but used the secondary data. This
limitation can result in some biases. Second, low sensitivity and
high specificity in weighted estimates occurred when identifying
persons who use illicit drugs from administrative claim data.[26]
Third, other factors involved in reducing opioid overdose death
rates have not be considered and, therefore, not controlled. This
is particularly true in terms of assessing the actual impact of
legalization of layperson naloxone possession on death rates.
Beyond NALs, other conditions may have influenced clinical
outcomes. In addition, only northeast and west regions were
investigated in this study in order tominimize neighboring effects.
Thus, further studies should be warranted to assess that increased
naloxone accessibility decreases opioid overdose deaths in other
regions after controlling for confounding factors. Fourth,
whether or not more laypersons possessed and used naloxone
for rescue after establishment of NALs is difficult to surmise,
although there is some indirect evidence. Nationwide naloxone
dispensing increased nearly 8-fold from the 4th quarter of 2015
to the 2nd quarter of 2017.[10] The Surgeon General emphasized
the importance of awareness and distribution of naloxone to the
public. This study demonstrated that layperson possession might
be associated with reduced growth of the opioid overdose death
rate. In addition, because of the possibility of under-reporting of
overdose deaths or lag times from coroner reports, the data may
underestimate opioid overdose deaths. Fifth, we used the state-
level data that could distort the results than the county- or city-
level data. Despite these potential limitations, the strength of this
study is provision of several new insights into the opioid crisis
from a public health perspective. This study demonstrated the
association between NAL provisions (possession vs distribution)
and their effects on opioid overdose death according to
geographic location (Northeast vs West).
In conclusion, we found that the greater was the access to
naloxone, the lower were the drug overdose death rates. Age-
adjusted drug overdose death rates in states that allowed
layperson distribution were lower than those in states that did
not. These death rates showed a similar pattern according to
layperson possession; the death rates were lower in states that
allowed layperson possession than in states that did not. These
findings support the assertion that improved naloxone accessi-
bility will ameliorate drug overdose death.
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